Media coverage about Adaptimmune Therapeutics (NASDAQ:ADAP) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Adaptimmune Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.1956692723595 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Adaptimmune Therapeutics (ADAP) opened at $7.17 on Tuesday. Adaptimmune Therapeutics has a 1-year low of $3.81 and a 1-year high of $9.29.
ADAP has been the subject of several research analyst reports. BidaskClub upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. SunTrust Banks restated a “buy” rating and issued a $10.00 price objective on shares of Adaptimmune Therapeutics in a research note on Friday, November 10th. Leerink Swann restated an “outperform” rating and issued a $15.00 price objective on shares of Adaptimmune Therapeutics in a research note on Friday, September 8th. ValuEngine downgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research upgraded shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $11.58.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.